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Background: Expression of the cellular karyopherin TNPO3/transportin-SR2/Tnp3 is necessary for HIV-1 infection.
Depletion of TNPO3 expression in mammalian cells inhibits HIV-1 infection after reverse transcription but prior to
integration.
Results: This work explores the role of cleavage and polyadenylation specificity factor subunit 6 (CPSF6) in the
ability of TNPO3-depleted cells to inhibit HIV-1 infection. Our findings showed that depletion of TNPO3 expression
inhibits HIV-1 infection, while the simultaneous depletion of TNPO3 and CPSF6 expression rescues HIV-1 infection.
Several experiments to understand the rescue of infectivity by CPSF6 were performed. Our experiments revealed
that the HIV-1 capsid binding ability of the endogenously expressed CPSF6 from TNPO3-depleted cells does not
change when compared to CPSF6 from wild type cells. In agreement with our previous results, depletion of TNPO3
did not change the nuclear localization of CPSF6. Studies on the formation of 2-LRT circles during HIV-1 infection
revealed that TNPO3-depleted cells are impaired in the integration process or exhibit a defect in the formation of 2-LTR
circles. To understand whether the cytosolic fraction of CPSF6 is responsible for the inhibition of HIV-1 in TNPO3-
depleted cells, we tested the ability of a cytosolic full-length CPSF6 to block HIV-1 infection. These results demonstrated
that overexpression of a cytosolic full-length CPSF6 blocks HIV-1 infection at the nuclear import step. Fate of the capsid
assays revealed that cytosolic expression of CPSF6 enhances stability of the HIV-1 core during infection.
Conclusions: These results suggested that inhibition of HIV-1 by TNPO3-depleted cells requires CPSF6.Background
TNPO3, transportin-SR2 or Tnp3 is a member of the
karyopherin β superfamily of proteins, and works as a
nuclear import receptor for serine-arginine-rich (SR)
proteins, which are necessary for RNA splicing. It is an
established fact that depletion of TNPO3 decreases the
ability of wild type HIV-1 and other lentiviruses to infect
cells [1-10]; however, the mechanism by which TNPO3
assists HIV-1 replication is under intense investigation
with existing evidence to support a role for TNPO3 after
reverse transcription but prior to integration [1-3,5,11].
Genetic and biochemical evidence suggests that the
HIV-1 capsid is the viral determinant for the require-
ment of TNPO3 during infection [1,6,12,13]. One of the* Correspondence: Felipe.Diaz-Griffero@einstein.yu.edu
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reproduction in any medium, provided the ormost important pieces of evidence supporting this no-
tion is an HIV-1 virus bearing the capsid mutation
N74D (HIV-1-N74D), which results in a virus insensitive
to the depletion of TNPO3 [1,3,6,12]. Interestingly, the
capsid mutation N74D was isolated by serial passage of
HIV-1 viruses in human T-cells expressing a fragment
derived from the cleavage and polyadenylation specificity
factor subunit 6 (CPSF6) protein, which blocks HIV-1
infection before nuclear import [12]. The fact that HIV-
1-N74D is insensitive to TNPO3-depletion and over-
comes the restriction imposed by a fragment derived
from CPSF6 suggests a role for CPSF6 in the ability of
TNPO3-depleted cells to block HIV-1 infection.
The fragment derived from CPSF6 composed of resi-
dues 1-358 (CPSF6-358) localizes to the cytoplasm and
potently restricts HIV-1 infection when overexpressed in
different mammalian cells [12]. By contrast the full-length
CPSF6 is a nuclear protein that when overexpressed in
mammalian cells does not block lentiviral infection [12].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion before nuclear import, CPSF6-358 might be inter-
acting with the incoming viral core. In agreement with
this notion, CPSF6-358 contains an HIV-1 capsid-binding
domain [14].
This work tested the role of CPSF6 in the ability of
TNPO3-depleted cells to inhibit HIV-1 infection. Deple-
tion of TNPO3 expression inhibits HIV-1 infection; how-
ever, the simultaneous depletion of TNPO3 and CPSF6
expression rescues HIV-1 infectivity indicating that CPSF6
is required for the ability of TNPO3-depleted cells to
block HIV-1 infection. To further understand the contri-
bution of CPSF6, we tested the binding of endogenously
expressed CPSF6 to the HIV-1 capsid extracted from wild
type and TNPO3-depleted HeLa cells; these experiments
revealed no difference in binding. CPSF6 localization stud-
ies in TNPO3-depleted cells showed that CPSF6 did not
change localization. Because depletion of TNPO3 prevents
HIV-1 infection after nuclear import, we studied the for-
mation of 2-LTR circles blocking the enzymatic activity of
HIV-1 integrase by genetic or pharmacological means.
Our studies revealed that TNPO3-depleted cells are im-
paired in the integration process or exhibit a defect in the
formation of 2-LTR circles. Because TNPO3-depleted cells
inhibit HIV-1 infection in a CPSF6-dependent manner, we
tested whether TNPO3-depleted cells inhibit HIV-1 infec-
tion by the mechanism used by CPSF6-358. For this pur-
pose, we tested the ability of a cytosolic full-length CPSF6
to block HIV-1 infection. These results demonstrated that
overexpression of a cytosolic full-length CPSF6 blocks
HIV-1 infection at or before the nuclear import step.
Overall these results suggested that inhibition of HIV-1 by
TNPO3-depleted cells is CPSF6-dependent.
Results
Inhibition of HIV-1 infection by depletion of TNPO3
requires expression of CPSF6
To understand the role of CPSF6 in the ability of TNPO3-
depleted HeLa cells to inhibit HIV-1 infection, we mea-
sured HIV-1 infectivity in HeLa cells simultaneously
silenced for the expression of TNPO3 and CPSF6
(Figure 1). Initially, we stably knockdown the expression of
TNPO3 by stably transducing HeLa cells with a specific
shRNA against TNPO3 [1]. As shown in Figure 1A, trans-
fection of TNPO3 K.D. cells by a specific siRNA against
CPSF6 decreased the expression CPSF6 by 20-fold when
compared to the non-target siRNA. Similarly, transfection
of HeLa control cells stably transduced with the empty
shRNA vector (pLKO.1) by siRNA against CPSF6 decreased
expression by 20-fold when compared to non-target siRNA.
Next we tested the ability of HIV-1 to infect HeLa cells
that are simultaneously silenced for the expression of
TNPO3 and CPSF6. As shown in Figure 1B, depletion of
TNPO3 and CPSF6 completely rescues HIV-1 infectionwhen compared to TNPO3 K.D. HeLa cells transfected
with a non-target siRNA. As expected TNPO3 K.D. HeLa
cells potently inhibit HIV-1 infection [1]. Interestingly,
depletion of CPSF6 alone did not affect HIV-1 infection
(Figure 1B). As control, we challenged the different knock-
down cells with HIV-1-N74D, a TNPO3-independent
virus [1,3,6,12]. These control experiments revealed that
simultaneous depletion of TNPO3 and CPSF6 does not
affect HIV-1-N74D infection (Figure 1B). Overall, these
experiments indicated that CPSF6 is required for the abil-
ity of TNPO3-depleted cells to inhibit HIV-1 infection.
Binding of endogenously expressed CPSF6 to HIV-1
capsid in the absence of TNPO3
Previous work has demonstrated the ability of CPSF6-358
fragment to bind in vitro assembled HIV-1 CA-NC com-
plexes, suggesting that the CPSF6-358 fragment might be
interacting with the incoming HIV-1 core [12,14]. We ini-
tially tested the ability of endogenously expressed CPSF6 to
bind in vitro assembled wild type and mutant (N74D) HIV-
1 capsid-nucleocapsid (CA-NC) complexes, as described
[15]. In agreement with the infectivity phenotype, endoge-
nously expressed CPSF6 in human 293 Tcells only interacts
with wild type HIV-1 CA-NC complexes (Figure 2A). To
further test specificity of our binding system, we tested the
ability of endogenously expressed CPSF6 to bind in vitro as-
sembled HIV-1 CA-NC complexes in the presence of the
HIV-1 small molecule inhibitor PF74 (PF-3450074) [16].
Interestingly, PF74 disrupts the binding of endogenously
expressed full-length CPSF6 to HIV-1 CA-NC complexes
demonstrating that the binding is specific (Figure 2B and
C), in agreement with a previous report that studies the
interaction of capsid with a 15-aminoacid peptide derived
from CPSF6 in the presence of PF74 [17]. As a negative
control, we measured the ability of PF74 to affect the bind-
ing of the restriction factor TRIMCyp to in vitro assembled
HIV-1 CA-NC complexes (Figure 2D). Altogether, these ex-
periments showed that the binding of CPSF6 to in vitro as-
sembled HIV-1 CA-NC complexes is specific.
Because TNPO3-depleted HeLa cells require full-
length CPSF6 for inhibition of HIV-1, we tested whether
depletion of TNPO3 affects the ability of CPSF6 to bind
HIV-1 capsid (Figure 2E). For this purpose, we measured
the ability of endogenously expressed CPSF6 from TNPO3-
depleted cells to bind in vitro assembled HIV-1 CA-NC
complexes. As shown in Figure 2E, endogenously expressed
CPSF6 from TNPO3-depleted cells bind in vitro assembled
HIV-1 CA-NC complexes similar to CPSF6 from shRNA
control cells. To show that extracts prepared using the cap-
sid binding buffer registered changes in cytosolic content,
we prepared extracts from HeLa cells stably expressing the
nuclearly localize CPSF6 and the cytoplasmicly localized
NES-CPSF6 (described below). As shown in Figure 2F, ex-
tracting with the capsid binding buffer showed more NES-
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prepared with the capsid binding buffer are able to register
changes in cytoplasmic content. As a control, we extracted
total protein using the whole cell extract buffer. Overall
these experiments showed that depletion of TNPO3 in
HeLa cells does not change the ability of CPSF6 to bind
in vitro assembled HIV-1 CA-NC complexes.Figure 1 Inhibition of HIV-1 infection by TNPO3-depleted cells requir
HeLa cells were transfected with a specific siRNA against CPSF6, a non-targ
were lysed, and the expression levels of CPSF6 and TNPO3 were monitored
respectively (A). As a loading control, cell lysates were Western blotted aga
reduction in the expression of CPSF6 when using siRNA against CPSF6 in s
control cells were challenged with increasing amounts of HIV-1 or HIV-1-N7
normalized by quantifying the particle-associated reverse transcriptase activ
determined forty-eight hours post-infection by measuring the percentage
obtained in three independent experiments and a representative experimeDepletion of TNPO3 does not change the localization of
CPSF6 but it changes the localization of ASF/SF2
Because CPSF6 is an SR protein, and TNPO3 is a nu-
clear import receptor for SR proteins, we tested whether
depletion of TNPO3 changes the subcellular localization
of CPSF6. As shown in Figure 3A, the subcellular distri-
bution of CPSF6 remained nuclear in TNPO3 K.D. cells,es expression of CPSF6. HeLa TNPO3 K.D. and shRNA control human
et siRNA, or left untreated. Forthy-eight hours after transfection, cells
by Western blot using antibodies against CPSF6and TNPO3,
inst GAPDH. Fluorescence quantification revealed a 20 and 18 fold
hRNA and TNPO3 K.D. cells, respectively. TNPO3 K.D. and shRNA
4D expressing GFP as a reporter for infection (B). Viruses were
ity on viral supernatants, as described in Methods. Infectivity was
of GFP-positive cells using a flow cytometer. Similar results were
nt is shown.
Figure 2 Binding of endogenously expressed CPSF6 to in vitro assembled HIV-1 CA-NC complexes. (A) Cellular extracts from human 293T
cells were incubated with wild type or mutant (N74D) in vitro assembled HIV-1 CA-NC complexes for 1 h. Samples were subsequently applied
onto 70% sucrose cushion and centrifuged, as described in Methods. A small fraction of each lysate was collected before centrifugation and
analyzed by Western Blotting using anti-CPSF6 antibodies (INPUT). Pelleted fractions (BOUND) were analyzed for the presence of CPSF6 and
HIV-1capsid (p24) by Western blotting using anti-CPSF6 and anti-p24 antibodies, respectively. (B, C) The ability of endogenously expressed CPSF6
from human 293T cells to bind in vitro assembled HIV-1 CA-NC complexes was measured in the presence of the small molecule PF74
(PF-3450074). (D) The ability of the restriction factor TRIMCyp to bind in vitro assembled HIV-1 CA-NC in the presence of PF74. (E) Similarly, we
measured the ability of endogenously expressed CPSF6 from TNPO3 K.D. and shRNA control HeLa cells to bind in vitro assembled HIV-1 CA-NC
complexes. (F) HeLa cells stably expressing the nuclearly localized CPSF6 and the cytoplasmicly localized NES-CPSF6 were lysed in capsid binding
buffer (10 mM Tris pH 7.4, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT) or whole cell extract buffer (50 mM Tris pH 8, 2 mM MgCl2, 280 mM NaCl, 0.5%
NP-40,10% Glycerol). Extracts were analyzed by Western blotting using antibodies against FLAG. As a control, we blotted extracts using antibodies
against the nuclear marker β-laminin. Similar results were obtained in three independent experiments and a representative experiment is shown.
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subcellular distribution of the SR protein alternative splic-
ing factor/splicing factor 2 (ASF/SF2), which is known to
interact with TNPO3 [18]. As shown in Figure 3A, the
cytosol of TNPO3 K.D. cells showed an increase of ASF/
SF2 when compared to shRNA control cells. Image quan-
tification is shown in Additional file 1. Altogether these
experiments showed that contrary to ASF/SF2, CPSF6
subcellular distribution does not change upon depletion of
TNPO3 expression. These observations are also in agree-
ment with our biochemical fractionation experiments
where CPSF6 remained nuclear in TNPO3 K.D. cells [1].
To further confirm that TNPO3-depleted cells do not
change the cellular distribution of CPSF6, we studied the
cellular localization of transiently transfected CPSF6 or
ASF/SF2 in TNPO3 K.D. cells (Figure 3B). For this purpose,
we transfected CPSF6-FLAG or ASF/SF2-FLAG in TNPO3K.D. cells, and study cellular distribution using anti-FLAG
antibodies. In agreement, we found that CPSF6-FLAG
did not change cellular distribution in TNPO3 K.D. cells
when compared to transfection of shRNA control cells
(Figure 3B). By contrast, ASF/SF2 mislocalized to the cyto-
plasm of TNPO3 K.D. cells when compared to transfec-
tions of shRNA control cells. Image quantification is shown
in Additional file 2. Overall, our findings suggested that
depletion of TNPO3 did not change the cellular distribu-
tion of CPSF6.
Effect of TNPO3-depletion on the generation of 2-LTR
circles during HIV-1 infection
To explore the role of TNPO3 during HIV-1 infection, we
challenged shRNA control and TNPO3 K.D. cells with
HIV-1 and HIV-1-N74D to measure the formation of 2-
LTR circles and productive infection 24 and 48 hours
Figure 3 Depletion of TNPO3 does not change the localization of CPSF6. (A) TNPO3 K.D. and shRNA control HeLa cells were fixed and
stained using specific antibodies against CPSF6 (red), ASF/SF2 (red) and TNPO3 (green), as described in Methods. The nuclear compartment was
labeled using DAPI. Image quantification is shown in Additional file 1. (B) TNPO3 K.D. and shRNA control HeLa cells were transiently transfected
using constructs expressing FLAG-tagged CPSF6 or ASF/SF2. Twenty-four hours post-transfection cells were fixed and immunostained using anti-
FLAG antibodies. The nuclear compartment was labeled using DAPI. Image quantification is shown in Additional file 2. Similar results were
obtained in three independent experiments and a representative experiment is shown.
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shown depletion of TNPO3 blocks HIV-1 infection after
nuclear import. Similarly, HIV-1-N74D was independent
of TNPO3 (Figure 4A).
After completion of reverse transcription the viral DNA
is translocated into the nucleus, where is integrated into
the cellular genome by the HIV-1 integrase or ligated to
form 2-LTR circles by nuclear ligases. To explore whether
depletion of TNPO3 impact the occurrence of these pro-
cesses, we performed infection of shRNA control and
TNPO3 K.D. cells with HIV-1 in the presence of the
integrase inhibitor raltegravir (RAL), and measure forma-
tion of 2-LTR circles and productive infection. As shown
in Figure 4B, the use of RAL, which blocks the integra-
tion of viral DNA into the cellular genome, increases
the amount of 2-LTR circles during HIV-1 infection
(Figure 4B); the increase of 2-LTR circles during HIV-1 in-
fection of shRNA control cells in the presence of ral-
tegravir suggested that most of the viral DNA was routed
to the formation of 2-LTR circles. Interestingly, we did not
observe an increase of 2-LTR circles during HIV-1infection of TNPO3 K.D. cells in the presence of raltegravir.
To corroborate these findings, we challenged TNPO3 K.D.
cells with an HIV-1 virus containing the integrase muta-
tion D116N (HIV-1-D116N), which results in a defec-
tive integrase [19,20]. Similarly, HIV-1-D116N infection
of TNPO3 K.D. cells did not exhibited an increase in the
levels of 2-LTR circles when compared to the infection
of wild type HIV-1 (Figure 4C). Overall these results
suggested that TNPO3-depleted cells are impaired in the
integration process or exhibit a defect in the formation of
2-LTR circles.
Expression of a cytosolic full-length CPSF6
We have demonstrated that inhibition of HIV-1 infec-
tion by TNPO3-depleted cells require full-length CPSF6.
To understand whether inhibition of HIV-1 by TNPO3
K.D. cells is due to the CPSF6 present in the cytoplasm,
we created a CPSF6 protein that localizes to the cyto-
plasm. For this purpose, we fused the full-length CPSF6
protein to the nuclear export signal of the protein kinase
inhibitor alpha (NES-CPSF6) [21] (Figure 5A). As a control,
Figure 4 TNPO3 K.D. cells block HIV-1 infection after nuclear import. (A) TNPO3 K.D. and shRNA control HeLa cells were challenged with
HIV-1 or HIV-1-N74D. Formation of 2-LTR circles and productive infection was measured twenty-four and forty-eight hours post-infection,
respectively. Formation of 2-LTR circles was measured by real-time PCR. Productive infection was determined by measuring the percentage of
GFP-positive cells by flow cytometry 48 hours post-infection. (B) Similarly, TNPO3 K.D. and shRNA control HeLa cells were challenged with HIV-1
in the presence of the HIV-1 integrase inhibitor raltegravir, and the formation of 2-LTR circles and productive infection was determined as
described above. (C) Formation of 2-LTR circles and productive infection was also measured by infecting TNPO3 K.D. and shRNA control HeLa
cells with HIV-1 and HIV-1-D116N, which is a virus that contain a defective integrase. Similar results were obtained in three independent
experiments and standard deviations are shown. Mock refers to control cells that were not infected. Viruses were normalized by quantifying the
particle-associated reverse transcriptase activity on viral supernatants, as described in Methods.
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(NES-CPSF6-FG284AA) (Figure 5A) [14]. We stably trans-
duced canine Cf2Th cells with the indicated CPSF6 variants
and measure protein expression by Western blot using
antibodies against FLAG (Figure 5B). To test whether the
NES changes the localization of CPSF6, we studied the sub-
cellular localization of the different CPSF6 variants by im-
munofluorescence microscopy. Contrary to the full-length
CPSF6 protein that exclusively localizes to the nucleus, the
NES-CPSF6 variants localized to the nucleus and the cyto-
plasm (Figure 5C). Similarly, the NES-CPSF6-FG284AA
also localized to the nucleus and cytoplasm. Image quantifi-
cation for Figure 5C is shown in Additional file 3.
Next, we tested the ability of the different CPSF6 vari-
ants to bind in vitro assembled HIV-1 CA-NC complexes.
As shown in Figure 5D, NES-CPSF6 bound in vitro as-
sembled HIV-1 CA-NC complexes as strong as the wild
type CPSF6. Interestingly, variants containing mutations
in the capsid binding region lost the ability to bind in vitro
assembled HIV-1 CA-NC complexes when compared to
wild type CPSF6 (Figure 5D). These results showed the
establishment of a cytosolic CPSF6.Cytosolic CPSF6 restricts HIV-1 replication after reverse
transcription but before or at nuclear import
We tested the ability of NES-CPSF6 to block HIV-1 infec-
tion. For this purpose, we challenged Cf2Th cells stably
expressing the different CPSF6 variants by increasing
amounts of HIV-1 expressing GFP as a reporter for infec-
tion. Contrary to CPSF6, the NES-CPSF6 variant potently
block HIV-1 infection (Figure 6A). In agreement with our
capsid binding assays, the NES-CPSF6-FG284AA variant
that contains a mutation in the capsid binding region did
not block HIV-1 infection (Figure 6A). As a control, we
performed similar infections using HIV-1-N74D, which is
insensitive to the block imposed by CPSF6-358 [12].
These results showed that expression of a cytosolic full-
length CPSF6 potently blocks HIV-1 infection.
To understand whether the inhibition of HIV-1 im-
posed by TNPO3-depleted cells is similar to the block
imposed by a cytosolic CPSF6, we investigated the viral
stage at which NES-CPSF6 blocks HIV-1. For this pur-
pose, we challenged Cf2Th cells stably expressing NES-
CPSF6 by HIV-1-GFP and measure the percentage of
GFP-positive cells (Figure 6B). Similar infections were
Figure 5 Expression of a cytosolic full-length CPSF6. (A) The wild type CPSF6 (NCBI Reference Sequence: NP_008938.2) protein with a C-terminal
FLAG epitope is depicted on top. The numbers of the amino acid residues at the boundaries of the different domains are indicated (RRM: RNA
recognition motive, Pro-rich: Proline-rich domain, RS: Arginine/Serine repeats). The HIV-1 capsid binding region is shown (residues 277-285). The
nuclear export signal of the protein kinase inhibitor α (NES-PKIα). The amino acid sequence of NES-PKIα is NELALKLAGLDI. The NES-PKIα was fused to
the N-terminus of CPSF6. (B) Cf2Th cells stably transduced with the different CPSF6 variants were analyzed for expression by Western blotting using
anti-FLAG antibodies. As a loading control, cell lysates were Western blotted against β-actin. (C) Intracellular distribution of the different CPSF6 variants
stably expressed in Cf2Th was studied by immunofluorescence microscopy, as described in Methods. The different CPSF6 variants were stained using
anti-FLAG antibodies (red). The cellular nuclei were stained by using DAPI (blue). Image quantification is shown in Additional file 3. (D) The ability of
the different CPSF6 variants to bind in vitro assembled HIV-1 CA-NC complexes was measured. 293T cells were transfected with plasmids expressing
the indicated CPSF6 variants. Thirty-six hours after transfection, cells were lysed. The lysates were incubated at room temperature for 1hour with
in vitro assembled HIV-1 CA-NC complexes. The mixtures were applied to a 70% sucrose cushion and centrifuged. INPUT represents the lysates
analyzed by Western blotting before being applied to the 70% sucrose cushion. The input mixtures were Western blotted using anti-FLAG antibodies.
The pellet from the 70% sucrose cushion (BOUND) was analyzed by Western blotting using anti-FLAG and anti-p24.
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post-infection, and the formation of 2-LTR circles
24 hours post-infection (Figure 6B). These results
showed that NES-CPSF6 blocks HIV-1 infection at the
level of nuclear import (Figure 6B), while HIV-1inhibition by TNPO3 K.D. HeLa cells occurs after nu-
clear import.
Next we tested the ability of cytosolic CPSF6 to re-
strict different viruses, including HIV-2, simian im-
munodeficiency virus from macaques (SIVmac), feline
Figure 6 Cytosolic CPSF6 expressed in Cf2Th cells restricts HIV-1 replication before or at the nuclear import step. (A) Cf2Th cells stably
expressing the indicated CPSF6 constructs were challenged with HIV-1 or HIV-1-N74D expressing GFP as a reporter. Forty-eight hours
post-infection the percentage of GFP-positive cells was determined by flow cytometry. As control, Cf2Th cells stably transduced with the empty
vector pLPCX were challenged with HIV-1 and HIV-1-N74D. (B) Cf2Th cells stably expressing CPSF6 and NES-CPSF6 were challenged with the
indicted viruses. Infection was determined by measuring the percentage of GFP-positive cells by flow cytometry 48 hours post-infection
(upper panel). In parallel, cells from similar infections were lysed at 7 or 24 hours post-infection and total DNA was extracted. The DNA samples
collected at 7 hours post-infection were used to determine the levels of late reverse transcripts by real-time PCR (middle panel). Separately, DNA
samples collected at 24 hours post-infection were used to quantify HIV-1 2-LTR circles by real-time PCR in DNA (lower panel). Mock refers to
control cells that were not infected. (C) Cf2Th cells stably expressing the different CPSF6 variants were challenged with HIV-2, SIVmac, FIV, BIV,
EIAV or N-MLV. As control, Cf2Th cells stably transduced with the empty vector pLPCX were challenged with HIV-2, SIVmac, FIV, BIV, EIAV or
N-MLV. Infectivity by the different viruses was determined by measuring the percentage of GFP-positive 48 hours post-infection. (D) Cf2Th cells
stably expressing the indicated CPSF6 variant or TRIM5αrh were challenged using similar amounts of HIV-1, and performed the fate of the capsid
assay to separate pelletable from soluble cytosolic capsids 16 hours post-infection as described in Methods. Input, soluble and pellet fractions
were analyzed by Western blotting using antibodies against HIV-1 CA p24. Similar results were obtained in three independent experiments and a
representative experiments is shown.
Fricke et al. Retrovirology 2013, 10:46 Page 8 of 14
http://www.retrovirology.com/content/10/1/46
Fricke et al. Retrovirology 2013, 10:46 Page 9 of 14
http://www.retrovirology.com/content/10/1/46immunodeficiency virus (FIV), bovine immunodeficiency
virus (BIV), equine infectious anemia virus (EIAV), and
N-tropic murine leukemia virus (N-MLV). In agreement
with previous observations [12], cytosolic CPSF6 inhibited
infection of HIV-2 and SIVmac (Figure 6C).
Because CPSF6 binds the HIV-1 core, we decided to test
whether the cytoplasmic CPSF6 (NES-CPSF6) influences
the stability of the HIV-1 core during infection. For this
purpose, we infected Cf2Th cells stably expressing NES-
CPSF6 or CPSF6 using similar amounts of HIV-1, and
performed the fate of the capsid assay 16 hours post-
infection as previously described [22]. Interestingly, NES-
CPSF6 increased the stability of the HIV-1 core during
infection by at least 10 fold (Figure 6D). As a control, we
observed the ability of TRIM5αrh to accelerate the un-
coating process of HIV-1 (Figure 6D). These results sug-
gested that NES-CPSF6 stabilizes the HIV-1 core during
infection preventing productive infection.
We performed similar experiments in the human cell
line HeLa. For this purpose, we stably expressed the dif-
ferent CPSF6 variants in human HeLa cells (Figure 7A).
In agreement NES-CPSF6 localized to the cytoplasm
of HeLa cells (Figure 7B). Image quantification is shown
in Additional file 4. NES-CPSF6 expressed in HeLa
cells blocked infection by HIV-1 but not HIV-1-N74D
(Figure 7C). Similar to our findings in Cf2Th cells, NES-
CPSF6 expressed in HeLa cells blocked HIV-1 infection
at the level of nuclear import (Figure 7D). In addition,
we found that NES-CPSF6 expressed in HeLa cells also
blocked infection of HIV-2 and SIVmac (Figure 7E).
Discussion
This work studied the role of CPSF6 in the inhibition of
HIV-1 by TNPO3-depleted cells. Our siRNA depletion
experiments showed that CPSF6 is necessary for the ability
of TNPO3-depleted cells to inhibit HIV-1 infection. The
contribution of CPSF6 to the ability of TNPO3-depleted
cells to inhibit HIV-1 infection might be due to a direct
effect of CPSF6 on HIV-1 infection. We favor three differ-
ent mechanisms by which CPSF6 might be necessary for
HIV-1 inhibition in TNPO3-depleted cells: 1) CPSF6 di-
rectly binds a viral component in the cytoplasm, 2) CPSF6
interacts with a viral component in the nucleus, or 3)
CPSF6 interacts with a component of the virus in the
cytoplasm and in the nucleus. To distinguish among
these models, we studied the HIV-1 capsid binding abil-
ity and the subcellular localization of endogenous CPSF6
in TNPO3-depleted cells. The ability of CPSF6 from
TNPO3-depleted cells to bind in vitro assembled HIV-1
CA-NC components did not change when compared to
CPSF6 from control cells. These experiments showed that
the ability of CPSF6 to bind the HIV-1 core is not affected
in TNPO3-depleted cell. Subcellular localization experi-
ments showed that the predominant nuclear localizationof full-length CPSF6 is unaffected in TNPO3-depleted
cells, which is in agreement with our biochemical frac-
tionation experiments [1]. The unchanged nuclear local-
ization of CPSF6 suggested that the effect of CPSF6 on the
virus occurs in the nucleus. Alternatively, our detection
methods might not be sensitive enough to detect subcellu-
lar distribution changes.
To further understand the role of CPSF6 in the inhi-
bition of HIV-1 observed in TNPO3-depleted cells, we
measured the levels of 2-LTR circles during infection of
TNPO3 K.D. cells. In agreement with previous observa-
tions [1-3,11], we found that TNPO3-depleted cells in-
hibit HIV-1 infection after nuclear import, as suggested
by the presence of 2-LTR circles. The use of raltegravir
or the HIV-1 mutant defective on Integrase D116N in
TNPO3 K.D. cells suggested that these cells might be
affecting integration or the formation of 2-LTR circles.
One possibility is that TNPO3 is important for a step in the
maturation process of the pre-integration complex, which
is essential for the integration to occur. Because TNPO3
also binds capsid [1,13], an interesting possibility is that
TNPO3 is recruited to the pre-integration complex by the
capsid in order to allow this maturation step to occur.
Overall, this evidence contributes to the notion that
TNPO3-depleted cells might be affecting the maturation
process of the pre-integration complex, which could result
in an HIV-1 integration defect, as previously suggested [13].
Because overexpression of a CPSF6 fragment, CPSF6-
358 [12], potently blocks HIV-1 infection, we tested
whether overexpression of a full-length CPSF6 protein in-
hibits HIV-1 infection. Differently from TNPO3-depleted
cells, overexpression of cytosolic full-length CPSF6 inhi-
bited HIV-1 infection before nuclear import. These ex-
periments suggested that the observed inhibition of HIV-1
by TNPO3-depleted cells is different from the inhibition
caused by overexpressing a full-length cytosolic CPSF6.
One possibility is that the stage of the block is related to
the expression levels of CPSF6 in the cytosol. For example,
at the endogenous levels of CPSF6 the block in TNPO3-
depleted cells is observed after nuclear import. However,
when CPSF6 is overexpressed in the cytosol of wild-type
HeLa cells the block is before or at nuclear import. Future
experiments will attempt to understand more mechanisti-
cally the role of CPSF6 in the observed HIV-1 inhibition in
TNPO3-depleted cells.
Conclusions
These results suggested that inhibition of HIV-1 by
TNPO3-depleted cells requires CPSF6.
Methods
Cell lines and plasmids
Human 293T cells, human HeLa cells and dog Cf2Th
cells were grown on DMEM supplemented with 10%
Figure 7 (See legend on next page.)
Fricke et al. Retrovirology 2013, 10:46 Page 10 of 14
http://www.retrovirology.com/content/10/1/46
(See figure on previous page.)
Figure 7 Cytosolic CPSF6 expressed in human HeLa cells restricts HIV-1 replication before or at the nuclear import step. (A) HeLa cells
were stably transduced with the indicated CPSF6 variant. Expression of the different CPSF6 variants was analyzed by Western blotting using anti-
FLAG antibodies. (B) The cellular distribution of the different CPSF6 variants was studied by immunofluorescence using anti-FLAG antibodies (red).
The nuclear compartment was stained using DAPI (blue). Image quantification is shown in Additional file 4. (C) HeLa cells stably expressing the
indicated CPSF6 variants were challenged with HIV-1 or HIV-1-N74D expressing GFP as a reporter for infection. Forty-eight hours post-infection
the percentage of GFP-positive cells was determined by flow cytometry. As control, HeLa cells stably transduced with the empty vector pLPCX
were challenged with increasing amounts of HIV-1 and HIV-1-N74D. (D) HeLa cells stably expressing CPSF6 and NES-CPSF6 were challenged with
the indicted viruses. Infection was determined by measuring the percentage of GFP-positive cells by flow cytometry 48 hours post-infection
(upper panel). In parallel, similarly infected cells were lysed at 7 or 24 hours post-infection and total DNA was extracted. The DNA samples
collected at 7 hours post-infection were used to determine the levels of late reverse transcripts by real-time PCR (middle panel). DNA samples
collected at 24 hours post-infection were used to quantify HIV-1 2-LTR circles by real-time PCR (lower panel). Mock refers to control cells that
were not infected. (E) HeLa cells expressing the different CPSF6 variants were challenged with HIV-2, SIVmac, FIV, BIV or EIAV. As control, HeLa
cells stably transduced with the empty vector pLPCX were challenged with HIV-2, SIVmac, FIV, BIV or EIAV. Infectivity by the different viruses was
determined by measuring the percentage of GFP-positive 48 hours post-infection. Similar results were obtained in three independent
experiments and a representative experiments is shown.
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HeLa cells: TNPO3 K.D and shRNA control were con-
structed as previously described [1]. CPSF6 (NCBI Refer-
ence Sequence: NP_008938.2) fused to C-terminal FLAG
epitope was cloned in the pLPCX vector (Clontech) using
EcoRI site. The nuclear export signal of protein kinase
inhibitor α (amino acid sequence: NELALKLAGLDI)
was inserted on the N-terminus of CPSF6 by PCR-cloning.
Plasmids expressing the CPSF6 capsid binding mutants
(FG284AA) were created by site directed mutagenesis.
Constructs were confirmed by sequencing analysis.
Generation of Cf2Th cells stably expressing CPSF6 variants
Cf2Th cells were stably transduced with recombinant retro-
viruses containing the different CPSF6 variants. Recombi-
nant viruses were produced in 293T cells by co-transfecting
the LPCX plasmids with the pVPack-GP and pVPack-
VSV-G packaging plasmids (Stratagene). The pVPack-
VSV-G plasmid encodes the vesicular stomatitis virus G
envelope glycoprotein, which allows efficient entry into a
wide range of vertebrate cells [23]. Transduced dog Cf2Th
cells were selected in 4 μg/ml puromycin (Sigma).
Western blot analysis
Cellular proteins were extracted with radioimmunopre-
cipitation assay (RIPA) as previously described [15]. Detec-
tion of proteins by Western blotting was performed using
anti-FLAG (Sigma), anti-CPSF6 (abcam), anti-GAPDH
(Ambion), anti-β-Actin (Sigma) or anti-p24 (Immuno Diag-
nostics) antibodies. Secondary antibodies against rabbit and
mouse conjugated to IRDye 680LT or IRDye 800CW were
obtained from LI-COR. Bands were detected by scanning
blots using the LI-COR Odyssey Imaging System in the
700 nm or 800 nm channel.
Infection with retroviruses expressing the green
fluorescent protein (GFP)
Recombinant retroviruses expressing GFP, pseudotyped
with the VSV-G glycoprotein, were prepared as described[24]. For infections, 6 × 104 cells seeded in 24-well plates
were incubated with the indicated retrovirus for 48 hours
at 37°C. The percentage of GFP-positive cells was deter-
mined by flow cytometry (Becton Dickinson). Viral stocks
were titrated by serial dilution on dog Cf2Th cells.HIV-1 CA-NC expression and purification
The HIV-1 CA-NC protein was expressed, purified and as-
sembled as previously described [15]. The pET11a expres-
sion vector (Novagen) expressing the CA-NC protein of
HIV-1 was used to transform BL-21(DE3) E. coli. CA-NC
expression was induced with 1 mM isopropyl-β-D-thio-
galactopyranoside (IPTG) when the culture reached an op-
tical density of 0.6 at 600 nm. After 4 hours of induction,
the cells were harvested and resuspended in 20 mM Tris-
HCl (pH 7.5), 1 μM ZnCl2, 10 mM 2-mercaptoethanol
and protease inhibitors (Roche). Lysis was performed by
sonication, and debris were pelleted for 30 minutes at
35,000×g. Nucleic acids were stripped from the solution by
using 0.11 equivalents of 2M (NH4)2SO4 and the same vol-
ume of 10% polyethylenimine. Nucleic acids were removed
by stirring and centrifugation at 29,500×g for 15 minutes.
The protein was recovered by addition of 0.35 equivalents
of saturated (NH4)2SO4. The protein was centrifuged at
9,820×g for 15 minutes and resuspended in 100 mM NaCl,
20 mM Tris-HCl (pH 7.5), 1 μM ZnCl2 and 10 mM 2-
mercaptoethanol. Lastly the CA-NC protein was dialyzed
against 50 mM NaCl, 20 mM Tris-HCl (pH 7.5), 1 μM
ZnCl2 and 10 mM 2-mercaptoethanol, and stored at -80°C.In vitro assembly of wild type and N74D HIV-1 CA-NC
complexes
HIV-1 CA-NC particles were assembled in vitro by di-
luting the CA-NC protein to a concentration of 0.3 mM
in 50 mM Tris-HCl (pH 8.0), 0.5 M NaCl and 2 mg/ml
DNA oligo-(TG)50. The mixture was incubated at 4°C
overnight and centrifuged at 8,600×g for 5 minutes. The
pellet was resuspended in assembly buffer (50 mM Tris-
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tion of 0.15 mM, and stored at 4°C until needed.
Binding of CPSF6 to in vitro assembled HIV-1 CA-NC
complexes
To study the binding of endogenous CPSF6 to in vitro
assembled HIV-1 CA-NC complexes, we lysed 2x106
HeLa or 293T cells in capsid binding buffer (10 mM
Tris-HCl pH 7.4, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
DTT) and incubated for 15 min at 4°C. The lysates were
centrifuged in a refrigerated Eppendorf microcentrifuge
(~14,000×g) for 15 minutes. To test the binding of the
different CPSF6 variants, human 293T cells were trans-
fected with the different CPSF6 plasmids. 400 μl of cell
lysates were incubated with 5 μl of in vitro assembled
HIV-1 CA-NC complexes and incubated at room tem-
perature for 1 hour. A portion of this mixture, henceforth
referred to as “INPUT” was stored. The mixture was spun
through a 70% sucrose cushion (70% sucrose, 1X PBS and
0.5 mM DTT) at 100,000×g in an SW55 rotor (Beckman)
for 1h at 4°C. After centrifugation, the supernatant was
carefully removed and the pellet was resuspended in 1X
SDS-PAGE loading buffer and henceforth referred to as
(BOUND). The level of CPSF6 proteins was determined
by Western blotting using anti-CPSF6 or anti-FLAG anti-
bodies. The level of HIV-1 CA-NC protein in the pellet
(BOUND) was assessed by Western blotting using anti-
p24 antibodies.
siRNA transfection
siRNA smart pool targeting CPSF6 (Dharmacon, ON-
TARGETplus SMARTpool L-012334-01-005; targeting
Human CPSF6, NCBI Reference Sequence: NM_007007)
was used to transiently silence CPSF6 expression in
TNPO3 K.D. and shRNA control HeLa cells. All siRNA ex-
periments were performed with oligofectamine (Invitrogen,
12252-011) according to manufacturer’s protocol with no
modification. DMEM without serum was used instead of
Opti-MEM medium. The amount of siRNA smart pool to
efficiently silence CPSF6 was 100 nM. Forty-eight hours
post-transfection, cells were challenged with increasing
amounts of the indicated HIV-1 viruses. Infections were
incubated for 48 hours, and infectivity was determined
by measure the percentage of GFP-positive cells using a
flow cytometer.
Quantification of particle associated reverse transcriptase
activity
Particle-associated reverse transcriptase was measured
as previously described [25]. 1 ml of virus was divided
into 3 separate samples and spun at 12000 rpm, 4ºC for
1h. The pellet was resuspended by vortexing in 12 μl of
RT suspension buffer (50 mM Tris-HCL pH 7.5, 1mM
DTT, 20% Glycerol, 250 mM KCl, 0.25% Triton X-100).Each sample was Freeze-thaw and vortexed 3 times. 50 μl
of RT assay reaction mix (50 mM Tris-HCl pH 7.5, 7.5 mM
MgCl2, 0.05% Triton X-100, 5.5 mM DTT, 0.6 u/ml Poly
[A] p[dT]10 (Sigma, p-4797) ,24 μCi/ml
3H-dTTP) was
added to each sample and it was incubate at 37ºC for 1h.
The samples were pipetted into a small Whatman filter
(DE81), soaked in SSC buffer (30 mM Na-citrate-HCl
pH 7, 250 mM NaCl), washed 3 times for 10 min in SSC
buffer and washed 2 times for 10 sec in 95% Ethanol. The
filter was dried and the radioactivity of 3H was measured
using a Scintillation Counter (Perkin Elmer).
Transfections and immunofluorescence microscopy of
FLAG-tagged proteins
Transfections of cell monolayers were performed using
Lipofectamine Plus reagent (Invitrogen), according to the
manufacturer’s instructions. Transfections were incubated
at 37ºC for 24 h. Indirect immunofluorescence microscopy
was performed as previously described [26]. Transfected
monolayers grown on coverslips were washed twice with
PBS and fixed for 15 min in 3.9% paraformaldehyde in PBS.
Fixed cells were washed twice in PBS, permeabilized for
4 min in permeabilizing buffer (0.5% TritonX-100 in PBS),
and then blocked in PBS containing 2% bovine serum albu-
min (blocking buffer) for 1 h at room temperature. Cells
were then incubated for 1 h at RT with primary antibodies
diluted in blocking buffer. After three washes with PBS,
cells were incubated for 30 min in secondary antibodies
and 1 mg/ml of DAPI (4′,6-diamidino-2-phenylindole).
Samples were mounted for fluorescence microscopy by
using the Pro Long Antifade Kit (Molecular Probes,
Eugene, OR). Images were obtained with a Zeiss Observer
Z1 microscope using a 63X objective, and deconvolution
was performed using the software AxioVisionV4.8.1.0
(Carl Zeiss Imaging Solutions).
Immunofluorescence microscopy of endogenously
expressed TNPO3, CPSF6 and ASF/SF2 in HeLa cells
4x104 TNPO3 K.D. or shRNA control HeLa cells were
seeded on 12-mm-diameter glass discs (Fisher Scientific)
and incubated at 37ºC overnight. Cells were fixed in 4%
paraformaldehyde (Electron Microscopy Sciences, cat.
15710) in PBS for 30 minutes, washed twice in PBS.
Samples were the incubated in 0.1 M glycine dissolved
in PBS (Sigma) two times for 5 minutes and washed in
PBS. Cells were incubated in permeabilization and block-
ing buffer (0.1% Triton-X 100 and 5% normal goat serum
and 0.2% BSA) for 30 minutes. Cells were incubated over-
night with primary antibodies in permeabilization and
blocking buffer. The TNPO3 protein was stained using
rabbit (Abcam cat# ab65016) or a mouse (cat# ab54353)
anti-TNPO3 antibody. The CPSF6 protein was stained
using a rabbit anti-CPSF6 antibody (Novus Biological cat#
NB100-61596). The ASF/SF2 protein was stained using a
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cat# cs-73026). Cells were washed three times in permea-
bilization and blocking buffer. Secondary antibodies were
applied at a dilution of 1:1000 (anti-rabbit Cy3-conjugated
antibodies, Jackson ImmunoResearch, cat#711-165-152
and anti- mouse Cy3-conjugated antibodies, Jackson Im-
munoResearch, cat#715-165-151) or 1:500 (anti-mouse
Alexa Fluor488-conjugated antibodies, Invitrogen, cat# A-
11001 and anti-rabbit Alexa Fluor488-conjugated anti-
bodies, Invitrogen, A-11094) for 1h and washed with PBS.
Cells were stained with DAPI for 3-5min, following 3
washes with PBS. Subsequently, samples were mounted for
fluorescent microscopy by using the FluorSave reagent
(Calbiochem, cat. 345789). Images were obtained with a
Zeiss Observer.Z1 microscope using a 63X objective. Im-
ages were deconvolved by using a defined point spread
function in the software AxioVision V4.8.1.0 (Carl Zeiss
Imaging Solutions).Quantitative real-time PCR for detection of HIV-1 and HIV-
1-N74D late reverse transcripts (LRT) and 2-LTR circles
1x106 cells were seeded in 10cm plates and challenged by
Dpn1-pretreated viruses, including HIV-1, HIV-1-N74D or
HIV-1-N116D. As control, we used heat inactivated viruses
for 30 min at 100˚C. Total cellular DNA was harvested
7 hours post-infection to measure late reverse transcripts
by real-time PCR. Similar infections were harvested
24 hours after infection for the measurement of 2-LTR cir-
cles by real-time PCR. Total cellular DNA was extracted
by using the QIAamp DNA mini kit (QIAGEN). For the
specific detection of late reverse transcript by real-time
PCR, we used the following primers and probe: 5′
GACGTAAACGGCCACAAG3′, 5′GGTCTTGTAGTTG
CCGTCGT3′ and 5′/56-FAM/CCTACGGCAAGCTGA
CCC /36-TAMSp/-3. A standard curve was created using
the GFP sequence of the HIV-1 reporter virus. Similarly,
for the detection of 2-LTR circles, we used the following
primers and probe: 5′ACCTAGGGAACCCACTGCTT
AAG3′, 5′ TCC ACAGATCAAGGATATCTTGTC3′ and
probe 5-/56-FAM/ACACTACTTGAAGCA CTCAAGGC
AAGCTTT/36-TAMSp/-3. A standard curve was created
using the pUC2LTR plasmid, which contains the HIV-1 2-
LTR junction.
DNA samples for real-time PCR from human cells
were normalized by amplification of the β-actin house-
keeping gene using the following primers using SYBR
Green(cat# 4309155): 5′ AACACCCCAGCCATGTAC
GT3′ and 5′ CGGTGAGGATCTTCATGAGGTAGT 3′.
DNA samples for real-time PCR from canine Cf2Th
cells were normalized by amplification of canine actin
housekeeping gene using the following primers by SYBR
Green: 5′GCATCCTGACCCTCAAGTAG 3′ and 5′
ACATACATGGCTGCTGGGGTGTT3′.Fate of the capsid assay
The fate of the capsid assay was performed as previously
described [27]. HIV-1 virus-like particles (VLPs) were pro-
duced by calcium phosphate co-transfection of plasmids
containing the following genes: HIV-1 gag-pol, VSV-G en-
velope and rev protein at a weight:ratio 15:3:1. Stably
transduced Cf2Th (1.5 × 106) cells expressing the indi-
cated proteins were seeded in 80 cm2 flasks. The following
day, the cells were incubated with 5-10 ml (approximately
2.5- 5.0 × 105 reverse transcriptase units) of HIV-1 at 4°C
for 30 minutes to allow viral attachment to the cells. The
cells were then shifted to 37°C until they were harvested
16 hours post-infection. Cells were washed three times
using ice-cold PBS and detached by treatment with 1.0 ml
of pronase (7.0 mg/ml in DMEM) for 5 minutes at 25°C.
The cells were then washed three times with PBS. The
cells were resuspended in 2.5 ml hypotonic lysis buffer
(10 mM Tris-HCl, pH 8.0, 10 mM KCl, 1 mM EDTA and
one complete protease inhibitor tablet) and incubated on
ice for 15 minutes. The cells were lysed using 15 strokes
in a 7.0 ml Dounce homogenizer with pestle B. Cellular
debris were cleared by centrifugation for 3 minutes at
3000 rpm. To allow assessment of the INPUT for HIV-1
p24, 100 μl of the cleared lysate were collected, made 1x
in SDS sample buffer, and analyzed by Western blotting.
Then 2.0 ml of the cleared lysate were layered onto a
50% sucrose (weight:volume) cushion in 1x PBS and cen-
trifuged at 125,000 x g for 2 hours at 4°C in a Beckman
SW41 rotor. Following centrifugation, 100 μl of the top-
most portion of the supernatant were collected and made
1x in SDS sample buffer; this sample is referred to as the
SOLUBLE p24 (HIV-1 CA) fraction. The PELLET was
resuspended in 50 μl 1x SDS sample buffer and is referred
to as the particulate p24. All samples were then subjected
to SDS-PAGE and Western blotting. The HIV-1 p24 pro-
teins were detected using a mouse anti-p24 antibody
(Immunodiagnostics).Additional files
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